Proposal accepted

Demand Johnson & Johnson stop global sales of cancer-causing products

We want Johnson & Johnson to stop the sale of its talc-based powder globally. Shockingly, Johnson & Johnson continues to say that their product is “safe” even though long-term use of talcum powder has been linked to multiple cancers including ovarian cancer and mesothelioma.

Investors are eligible to vote at Johnson & Johnson's upcoming AGM on Thursday, April 28, 2022 if they held shares by the close of business on March 1, 2022* See below for more information

Our Goal

Tulipshare has submitted a proposal to Johnson & Johnson demanding the termination of global sales of the company’s talc-based powder. By investing in our campaign, you’re adding your voice to a call-to-action seeking to hold Johnson & Johnson accountable and putting an end to the sale of this known cancer-causing product globally, not just in North American markets.

Why It's Important

Johnson & Johnson’s talc-based Baby Powder (talcum powder) was shown to contain traces of asbestos - a carcinogen known to cause cancer with no safe exposure level. What’s worse is that Johnson & Johnson reportedly knew about the asbestos contamination, yet continued to heavily market the product to minority, overweight women.

How Tulipshare works

We identify opportunities for ethical change at public companies

These opportunities are identified through our own research analysts and the community we’ve built at Tulipshare. We then work with our legal team to verify and build our campaign.

We work to acquire company shares so that we can engage as an investor

Unfortunately, there’s a minimum investment threshold to be able to vote and propose changes at public companies. That’s why we created Tulipshare - so that we can unify the investing power of like-minded individuals to drive change from within.

We leverage the collective shares of our investor community

Once we acquire enough shares, we start discussions with the company to promote ethical change. This isn’t always easy and the company may object to our requests. However we keep our investors informed of progress and all communications - so you’re aware of what’s happening every step of the way.

Stock info

Johnson & Johnson

JNJ

$176.98

Past performance is not indicative of future results

Johnson & Johnson

JNJ

$176.98

1469

people are interested

Your capital is at risk. This stock trading platform is facilitated by Tulipshare.Tulipshare does not provide investment advice. Individual investors should make their own decisions or seek professional independent advice if they are unsure as to the suitability/appropriateness of any investment for their individual circumstances or needs, including potential tax treatment. The value of investments can go up as well as down and you may receive less than your original investment or lose the value of your entire initial investment. Past performance is not a reliable indicator of future results. Currency rate fluctuations can adversely impact the overall returns on your original investment. Learn more by reading our full Risk Disclosure and our FAQs.

Tulipshare Ltd. is an appointed representative of RiskSave Technologies Ltd which is authorised and regulated by the Financial Conduct Authority (FRN 775330).Payment services are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN:900199).© Tulipshare Ltd., 2022

Terms of ServiceContact us